Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you need them, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don’t need them, and old cells don’t die when they should. These extra cells can form a mass called a tumour.
Medical marijuana cannabis research relating to cancer suggests that cannabidiol (CBD) found in the cannabis or marijuana plant has the ability to reduce cancer in patients.
Tumours can be benign or malignant. Benign tumours aren’t cancer while malignant ones are. Cells from malignant tumours can invade nearby tissues. They can also break away and spread to other parts of the body.
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for where they start. For example, lung cancer starts in the lung, and breast cancer starts in the breast. The spread of cancer from one part of the body to another is called metastasis. Symptoms and treatment depend on the cancer type and how advanced it is. Most treatment plans may include surgery, radiation and/or chemotherapy. Some may involve hormone therapy, biologic therapy, or stem cell transplantation.
Types of Cancer
Medical Marijuana Efficiency
Cannabinoids, the active components of the strain ‘Sativa’ and their derivatives exert palliative effects in cancer patients by preventing nausea, vomiting and by stimulating appetite. They also have been found in some cases to exert curative effects by causing cell death and tumour reduction. They occur naturally in all cannabis plants. Currently there are 85 known separate cannabinoids in each plant. The two main cannabinoids, Delta 9 Tetrahydrocannabinol (THC) and Cannabidiol (CBD), are the most effective in the treatment of cancer.
Cannabinoids come into effect by binding to cannabinoid receptors (found in all humans) which fuel the endocannabinoid system producing similar chemical compounds to the cannabinoids.
Clinical Research on Cancer and Medical Marijuana Cannabis
- Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas
- Inhibition of tumor angiogenesis by cannabinoids
- Cannabis and Cannabinoids
- Cannabis, Cannabinoids and Cancer
- Cancer Brochure
- Cannabis and Pancreatic Cancer
- Cannabis and Ovarian Cancer
- Cannabis and Liver Cancer
- Cannabis and Bladder Cancer
- Cannabis and Mouth and Throat Cancer
- National Cannabis Institute: Cannabis and Cannabinoids
- Summary of Evidence for Cannabis and Cannabinoids
- Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells
- Former MD Anderson Scientist Cures Prostate Cancer
- The Endocannabinoid System and Cancer: Therapeutic Implication
- Toward the use of cannabinoids as antitumor agentsThe Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids
- A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain.
- Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.
- Spontaneous regression of septum pellucidum/forniceal pilocytic astrocytomas–possible role of Cannabis inhalation.
- Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain.
- A population-based case-control study of marijuana use and head and neck squamous cell carcinoma
- Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring.
- Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting.
- Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.
- A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme.
- Cannabinoids in the Management of Intractable Chemotherapy-Induced Nausea and Vomiting and Cancer-Related PainEffects of Smoked Cannabis and Oral ∆9-Tetrahydrocannabinol on Nausea and Emesis After Cancer Chemotherapy
- Marijuana to prevent nausea and vomiting in cancer patients: a survey of clinical oncologists.
- An efficient new cannabinoid antiemetic in pediatric oncology.
- Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting
- Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial.
- Nabilone: an alternative antiemetic for cancer chemotherapy
- Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting
- Tetrahydrocannabinol vs. prochlorperazine. The effects of two antiemetics on patients undergoing radiotherapy
- Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy
- A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy.
- Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine
- Comparative trial of the antiemetic effects of THC and haloperidol
- Physiologic observations in a controlled clinical trial of the antiemetic effectiveness of 5, 10, and 15 mg of delta 9-tetrahydrocannabinol in cancer chemotherapy. Ophthalmologic implications.
- Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis.
- Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis
- Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain